Levodopa reverses gait asymmetries related to anhedonia and magical ideation by Mohr, C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2005
Levodopa reverses gait asymmetries related to anhedonia and magical
ideation
Mohr, C; Landis, T; Bracha, H S; Fathi, M; Brugger, P
Abstract: Animals and men turn preferentially away from the hemisphere with the more active dopamine
(DA) system. Consistent with the idea of a right-hemispheric hyperdopaminergia in schizophrenia, a left-
sided turning bias was described for unmedicated psychotic patients. We investigated the modulating
role of DA and schizophrenia-like thought on whole-body turns in a controlled double-blind study. The
number of veers to either side when walking blindfolded straight ahead (20 meter) was assessed in 40
healthy righthanded men (20 men received levodopa, the remaining participants placebo). Side pref-
erences were analyzed in terms of individuals’ positive (Magical Ideation, MI) and negative (Physical
Anhedonia, PhysAn) schizotypal features. In the placebo group, increasing MI scores were related to in-
creasing left-sided veering and increasing PhysAn scores were related to increasing right-sided veering. In
the levodopa group, this relationship between preferred veering side and type of schizotypy was reversed.
The finding in the placebo group suggests an association between MI and a relative right-hemispheric hy-
perdopaminergia. Unexpectedly, levodopa did not enhance this veering bias, but reversed it, suggesting
that psychosis-protective mechanisms exist in the healthy positive ”schizotypic” brain. Also unexpect-
edly, levodopa made ”anhedonics” veer like ”magics” after placebo, suggesting that DA agonists suppress
negative schizotypal symptoms
DOI: https://doi.org/10.1007/s00406-004-0531-0
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-156645
Journal Article
Published Version
Originally published at:
Mohr, C; Landis, T; Bracha, H S; Fathi, M; Brugger, P (2005). Levodopa reverses gait asymmetries
related to anhedonia and magical ideation. European Archives of Psychiatry and Clinical Neuroscience,
255(1):33-39.
DOI: https://doi.org/10.1007/s00406-004-0531-0
Eur Arch Psychiatry Clin Neurosci (2005) 255 : 33–39 DOI 10.1007/s00406-004-0531-0
■ Abstract Animals and men turn preferentially away
from the hemisphere with the more active dopamine
(DA) system. Consistent with the idea of a right-hemi-
spheric hyperdopaminergia in schizophrenia, a left-
sided turning bias was described for unmedicated psy-
chotic patients. We investigated the modulating role of
DA and schizophrenia-like thought on whole-body
turns in a controlled double-blind study. The number of
veers to either side when walking blindfolded straight
ahead (20 meter) was assessed in 40 healthy right-
handed men (20 men received levodopa, the remaining
participants placebo). Side preferences were analyzed in
terms of individuals’positive (Magical Ideation,MI) and
negative (Physical Anhedonia, PhysAn) schizotypal fea-
tures. In the placebo group, increasing MI scores were
related to increasing left-sided veering and increasing
PhysAn scores were related to increasing right-sided
veering. In the levodopa group, this relationship be-
tween preferred veering side and type of schizotypy was
reversed. The finding in the placebo group suggests an
association between MI and a relative right-hemi-
spheric hyperdopaminergia. Unexpectedly, levodopa
did not enhance this veering bias, but reversed it, sug-
gesting that psychosis-protective mechanisms exist in
the healthy positive “schizotypic” brain. Also unexpect-
edly, levodopa made “anhedonics” veer like “magics” af-
ter placebo, suggesting that DA agonists suppress nega-
tive schizotypal symptoms.
■ Key words dopamine · asymmetry · hemispheres ·
schizotypy · turning · neuropharmacology
Introduction
Schizotypy is associated with a mild and non-clinical
“schizophrenia-like” thinking style in healthy popula-
tions and is commonly assessed by self-report question-
naires. The “schizotypy” concept, originally introduced
as a genetic diathesis-stress model for schizophrenia
(Meehl 1962),has frequently been applied in research on
psychosis-proneness (Chapman et al. 1994; Kwapil et al.
1997).The idea of a relationship between schizotypy and
overt clinical psychosis is supported by studies that
found that highly schizotypal subjects reveal cognitive
(Gooding et al.1999; Park et al.1995),attentional (Good-
ing et al. 2000; Sarkin et al. 1998), behavioral (Barnett
and Corballis 2002; Shaw et al. 2001) and physiological
(Klein et al. 1999; Pizzagalli et al. 2000) peculiarities
comparable to those described for patients with schizo-
phrenia. However, neuropsychological similarities be-
tween schizotypy and schizophrenia are not limited to
highly schizotypal subjects, but can also be observed in
random samples of participants (Kalaycioglu et al. 2000;
Brugger and Graves 1997; Mohr et al. 2003a; Taylor et al.
2002), for whom schizotypal features are quantitatively
less prominent yet qualitatively equivalent.
The advantage of the schizotypy approach to investi-
gate brain functioning in “psychosis-prone”populations
without illness-related epiphenomena such as prior psy-
ORIGINAL PAPER
Christine Mohr · Theodor Landis · H. Stefan Bracha · Marc Fathi · Peter Brugger
Levodopa reverses gait asymmetries related to anhedonia 
and magical ideation
Received: 5 December 2003 / Accepted: 5 May 2004 / Published online: 12 November 2004
EA
PC
N
 531
C. Mohr () · T. Landis
Functional Brain Mapping Laboratory
Dept. of Neurology
University Hospital Geneva
Rue Micheli-du-Crest 24
1211 Geneva 14
Fax: +41(0)223728358
E-Mail: Christine.Mohr@hcuge.ch
C. Mohr
Dept. of Rehabilitation
University Hospital Geneva
Geneva, Switzerland
C. Mohr · P. Brugger
Dept. of Neurology
University Hospital Zurich
Zurich, Switzerland
H. S. Bracha
Honolulu VA National Centre for PTSD
Honolulu, Hawaii, USA
M. Fathi
Clinical Chemistry Central Laboratory
University Hospital Geneva
Geneva, Switzerland
34
chosis, antipsychotic medication, and hospitalization
has well been recognized (e. g., Gooding et al. 1999; Clar-
idge et al. 1992; Taylor et al. 2002). This approach would
also offer a possibility to test for drug actions in un-
medicated healthy but “psychosis-prone” subjects. It
has, however, received surprisingly little direct (Kumari
et al. 1999; Williams et al. 1997) and indirect (Gray et al.
2002; Kopp et al. 2002) attention. In particular, the neu-
rotransmitter dopamine (DA) is an excellent candidate
for such an approach. Ever since the discovery that DA
antagonists ameliorate acute psychotic symptoms (e. g.,
Klein and Davis 1969; Matthysse 1973), it has been ac-
cepted that this neurotransmitter plays a major role in
the pathophysiology of schizophrenia (Laruelle and
Abi-Dargham 1999). Since DA agonists can not only
worsen positive psychotic symptoms in patients but also
trigger psychosis in healthy people (Abi-Dargham et al.
1998; Angrist et al. 1985; Davidson et al. 1987; Janowsky
and Risch 1979; Sekine et al. 2001), a hyperactive DA sys-
tem might be involved along the whole schizophrenia
spectrum. The DA metabolite homovanillin acid (HVA)
has been shown to positively correlate with positive di-
mension of symptoms in schizophrenia (Davidson and
Davis 1988; Pickar et al. 1984) and schizotypal personal-
ity disorder (Siever et al. 1991, 1993). Although the role
of DA for even mild forms of schizotypy was empha-
sized (Mohr et al. 2003a; Brugger and Graves 1997; Gray
et al.2002; Kopp et al.2002),direct relationships between
schizotypy and the DA system have rarely been investi-
gated (Kumari et al. 1999; Williams et al. 1997).
In the present study, we tested a DA-mediated behav-
ior, i. e., lateralized whole-body movements, in a lev-
odopa placebo controlled double-blind design. We as-
sessed veering behavior as a function of healthy
participants’ positive (magical ideation, MI; Eckblad
and Chapman 1983) and negative (physical anhedonia,
PhysAn, Chapman et al. 1976) schizotypal features. An
extensive literature in animals (Pycock 1983 for
overview), but also in patients with asymmetrical
Parkinson’s disease (Bracha et al. 1987) showed that
whole-body turns are directed towards the cerebral
hemisphere with the less active DA system. Thus, the
left-sided turning preference reported from unmed-
icated patients with positive psychotic symptoms was
taken as support for the notion of their relative hyper-
active right-hemispheric DA system (Bracha 1989;
Bracha et al. 1993). The magnitude of this left-sided
turning bias was not only correlated to symptom sever-
ity (Bracha et al. 1993) but was also absent in patients
treated with DA antagonists (Levine et al. 1997). How-
ever, this long-term spontaneous turning measure is not
suited to measure short-lasting drug effects in a con-
trolled experimental setting. Bracha and collegues used
a belt-mounted, direction-sensitive device monitoring
changes in the orientation of the dorsal-ventral axis
(Bracha et al. 1987). Unaware of the kind of measure-
ment, the individuals wore the device for several hours
during every-day activities. In more recent studies, we
showed dopaminergic mediation of veering behavior,
i. e., side deviations during blindfolded straight ahead
walking (Mohr et al. 2003b, 2004). Thus, veering can be
regarded as an experimentally controlled analogue to
the long-term spontaneous turning measure suited to
test for short-term drug effects. Interestingly, it was only
veering behavior and not stepping (walking blindfolded
on a given spot) behavior, which was under dopaminer-
gic control (Mohr et al. 2004). Moreover, we assessed
veering behavior as used in the present study as well as
spontaneous turning behavior in the same subjects
(Mohr et al. 2003a). Both measures were similarly mod-
ulated by enhanced MI scores; specifically, overall right-
sided spatial deviations were attenuated. In analogy to
the findings from patients with schizophrenia (Bracha
1989; Bracha et al. 1993), we suggest that schizotypy of
the positive type may be associated with a relatively hy-
peractive right-hemispheric DA system.
Since DA agonists led to psychotic relapses in pa-
tients with schizophrenia (Abi-Dargham et al. 1998; An-
grist et al. 1985; Davidson et al. 1987), and since the de-
gree of positive symptoms in these patients is correlated
with a left-sided spatial bias (Bracha et al. 1993), we hy-
pothesize that DA supplementation in high MI subjects
would enhance their left-sided veering tendency. To our
knowledge, no previous work has ever assessed the rela-
tionships between spatially directed whole-body move-
ments and negative symptoms, either in schizophrenic
patients or in schizotypal subjects. Hence, we do not for-
mulate any a priori hypothesis.
Methods
■ Subjects
A total of 40 healthy men were recruited by flyers and personal con-
tact. All of them were right-handed according to a 13-item handed-
ness questionnaire (Chapman and Chapman 1987). Their mean (±
SD) age was 25.1 ± 3.8 yrs. and their mean education was 16.9 ± 3.2
yrs. Subjects with any current medication, history of drug abuse or
neuropsychiatric illness, as assessed with an extended clinical inter-
view (Campbell 2000), had been excluded. Because of the potential of
DA agonists to trigger a psychotic breakdown (Janowsky and Risch
1979; Sekine et al. 2001), especially in subjects with high MI scores,
subjects scoring in the upper quartile of this scale (MI scores > 22; see
next paragraph) were also excluded, as required by the local ethics
committee. After complete description of the study to the subjects,
written informed consent was obtained.
■ Questionnaires
Magical ideation scale
We assessed subjects’ MI with a validated 30-item questionnaire
which includes items such as “I sometimes have a feeling of gaining
or losing energy when people look at me or touch me,” (keyed true)
or “Some people can make me aware of them just by thinking about
me” (keyed true). Scores on the MI scale range from 0–30, with higher
scores indicating more pronounced magical thinking. The scale is
published in full in Eckblad and Chapman (1983); Barnett and Cor-
ballis (2002), and normative data can be found in Garety and Wessely
(1994).
35
Physical anhedonia scale
This originally 61-item questionnaire (revised German version: 50-
items, Meyer and Hautzinger 1999; Scherbarth-Roschmann and
Hautzinger 1991) includes items about sensory, tactile and movement
experiences (Chapman et al. 1976). Illustrative items for this ques-
tionnaire are “On seeing a soft, thick carpet, I have sometimes had the
impulse to take off my shoes and walk barefoot on it” (keyed false)
and “Sex is OK but not as much fun as most people claim it is” (keyed
true). Scores on the PhysAn scale range from 0–50, with higher scores
indicating more pronounced PhysAn. The scale is published in full in
Chapman et al. (1976). Normative values of an American sample are
found in Chapman et al. (1980) and of a German sample in Meyer and
Hautzinger (1999).
■ Veering task
Subjects were positioned at the end of a corridor (width: 1.60 m;
length: 20 m). Before being blindfolded, each subject could visually
explore the corridor as well as the line along its middle. Subjects had
to go blind-folded, the ears plugged, and without shoes to the end of
the corridor. The experimenter walked in front of the subject. When
walking deviation from the line was larger than 0.2 m for both feet, the
subject was stopped and a veer to the respective side was counted.Af-
ter a veer, a metal strip was placed onto the line between subject’s feet.
This allowed reorientation to the line-course by touching the strip
with the feet. Start side in the corridor was counterbalanced between
subjects. The number of deviations (veers) to the left and right, re-
spectively, was summed.
■ Double-blind procedure
The study was a randomized, double-blind levodopa/placebo design.
A dual-release formulation of levodopa/benserazide (brand name:
Madopar® DR, Roche Pharma (Schweiz) AG, Reinach, Switzerland)
with a fast absorption within the first hour and sustained concentra-
tion levels thereafter (Gasser et al. 1999) was administered. Prior to
the study, subjects were informed about the experimental procedure
and the possible side effects of levodopa administration. Each subject
fasted overnight and arrived at 9 a. m. on the experimental day. Sub-
jects were also instructed not to consume any alcohol or other drugs
for at least 24 hours before testing. After having provided informed
consent, subjects received either Madopar® DR or a placebo. Subjects
consumed 200 ml water directly after substance administration, and
standardized breakfast was provided 15 min later. In order to ensure
that subjects were under significant levodopa concentration through-
out the experiment, two blood samples of about 5–7 ml each were
drawn. The first blood sample was collected 30 min after drug ad-
ministration before experiments started. The veering task was con-
ducted about one hour after the first blood sample.As soon as the ex-
periments were finished (about 120 min after the first blood sample),
a second blood sample was drawn.
■ Blood sample collection and analysis
The blood was collected in plastic tubes containing lithium hepari-
nate as an anticoagulant and plasma was separated by centrifugation.
The samples were stored immediately at –80 °C pending analysis. In a
first analytical step, to eliminate interfering substances, an internal
standard was added to the blood serum samples. Then, the blood
serum was fixed on activated alumina, in basic media, and thoroughly
vortexed. The liquid phase was discarded and the alumina was finally
washed with ultra-pure water. Then, levodopa and the internal stan-
dard were eluted in acidic media and determined by high-pressure
liquid chromatography (HPLC) with electrochemical detection
(ECD). The substances were separated on a reversed-phase column
and detected by ECD in amperometric mode. Quantification was
done by internal standard method. Analytical reproducibility was
10 % and the quantification limit was 3 ng/ml.
■ Data analyses
To investigate whether MI scores or PhysAn scores were related to
side-biases in the veering task, four Pearson Product-Moment corre-
lation analyses were calculated for each schizotypy scale and sub-
stance group, separately. Side-biases were determined by calculating
a difference score (number of left veers minus number of right veers).
Thus,positive values indicate a left-sided preference and negative val-
ues a right-sided preference. The values were correlated with the
schizotypy scores in the two substance groups, respectively. Normal
distribution to justify application of parametric statistics was con-
firmed by Kolmogorov-Smirnov tests (0.23 > d-values > 0.16, all p-
values > 0.20 for MI raw scores; PhysAn raw scores, and the difference
score for the two substance groups separately). If not otherwise
stated, all p-values are two-tailed.
Results
Due to an error in the randomization of placebo and lev-
odopa,21 subjects were in the placebo group and 19 sub-
jects in the levodopa group. Neither age (t38 = 0.74,
p = 0.45) nor education (t38 = 0.55, p = 0.59) differed be-
tween the placebo (age: 25.5 ± 3.5 yrs., education:
17.1 ± 2.9 yrs.) and levodopa group (age: 24.6 ± 4.2 yrs.;
education: 16.6 ± 3.6 yrs.). The ranges of observed MI
scores for the placebo group (1–20) and levodopa group
(2–21) overlapped1. The same was true, although to a
lesser extent, for the ranges of the PhysAn scores
(placebo: 1–27, levodopa: 3–22). Neither age (MI:
r = 0.11, p = 0.49; PhysAn: r = 0.05, p = 0.74) nor educa-
tion (MI: r = –0.06, p = 0.73; PhysAn: r = –0.02, p = 0.90)
were significantly correlated with MI and PhysAn
scores, respectively.
■ Levodopa concentrations
In the levodopa group, the mean levodopa serum con-
centration was 212.4 ng/ml (range: 5–953 ng/ml) for the
first blood sample and 137.2 ng/ml (range: 0–597 ng/ml)
for the second blood sample (t18 = 1.36, p = 0.19).A sim-
ilar number of subjects had higher levodopa concentra-
tions for the first (n = 11) and second sample (n = 8)
(Chi-square = 0.47, df = 1, p = 0.49). None of the subjects
reported any remarkable substance effect. Levodopa
serum concentrations in the placebo group were zero
throughout.
■ Schizotypy and veering behavior
The mean difference score was –0.1 ± 1.3 veers for the
whole population (possible range: –3.0 to 3.0). It did not
differ between the levodopa (0.2 ± 1.2) and placebo
1 As pointed out by an anonymous referee, future studies would ben-
efit from determining subjects’ schizotypy scores before pharmaco-
logical treatment. This would control 1) for the range of schizotypy
scores, which in the present experiment simply happened to be highly
similar in the levodopa and placebo groups, but also 2) for the distri-
bution of schizotypy scores within substance groups
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(–0.3 ± 1.3) group (t38 = 1.37, p = 0.18). The two correla-
tion analyses for the placebo group revealed a signifi-
cant relationship between MI scores and the difference
score (r = –0.52, p = 0.02). With increasing MI scores,
subjects displayed an increasing relative shift to the left
side (see Fig. 1A).The inverse relationship for increasing
PhysAn scores fell short of significance (r = 0.42,
p = 0.06). The two correlation analyses for the levodopa
group were both significant.Subjects with increasing MI
scores showed an increasing relative shift to the right
side (r = 0.49, p = 0.04, see Fig. 1). Increasing PhysAn
scores were associated with opposite lateral preferences
(r = –0.56, p = 0.01, see Fig. 1).
Discussion
It is not yet known whether DA plays a role in schizo-
typy, a mild non-pathological analogue to schizophre-
nia. We, therefore, assessed axial whole-body move-
ments, well established for its dopaminergic mediation,
to investigate the relationship between short-term lev-
odopa effects and schizotypal features. From the animal
literature (Pycock 1983) it is known that spontaneous
turning behavior occurs towards the hemisphere with
the less active DA system. In men with asymmetric DA
deficiencies, analogous turning preferences were de-
scribed (Bracha et al. 1987). These studies were mainly
based on a long-term spontaneous turning behavior not
suitable for the study of short-term drug effects. Conse-
quently, we tested the veering behavior during walking
blindfolded straight ahead. This behavior is reportedly
modulated by 1) dopamine (Mohr et al. 2003b, 2004),
and 2) a subject’s MI scores in similar ways as is spon-
taneous turning behavior (Mohr et al. 2003a).
In the present double-blind study,we found that veer-
ing tendencies after placebo or levodopa were inversely
related to individuals’ MI or PhysAn scores.As predicted
for the placebo group, increasing MI scores were signif-
icantly related to a shift towards the left hemispace. In-
creasing PhysAn scores were related to opposite side
preferences, although this relationship fell short of sta-
tistical significance. For the levodopa group, our predic-
tions failed.We did not find an enhancement of the veer-
ing bias found in the placebo group. On the contrary,
high PhysAn scores were associated with left-sided and
high MI scores with right-sided veering preferences. It
appears as if subjects with enhanced MI scores in the
levodopa group depict “normalized” or even reversed
(right-sided) veering preferences when compared to the
left-sided veering bias in individuals with enhanced MI
scores in the placebo group. Subjects with elevated
PhysAn scores in the levodopa group, on the other hand,
veered like subjects with elevated MI scores in the
placebo group.
The opposite side preferences with respect to MI and
PhysAn in the placebo group might simply be an ex-
pression of an overall high or low DA level, respectively,
leading to opposite hemispheric DA asymmetries. Glick
et al. (1982) measured DA concentrations in post-
mortem brain tissue from healthy subjects. They found
right greater than left hemisphere DA concentrations in
subjects with an overall high DA level, but a left greater
than right hemisphere DA concentration in those with
overall low DA level. High MI can be understood as a
non-clinical analogue to positive psychotic symptoms
(Eckblad and Chapman 1983) typically linked to a hy-
perdopaminergic state (Davis et al. 1991). Therefore, in
line with previous studies on schizophrenia (Bracha
1989; Bracha et al. 1993; Harvey et al. 1993; Posner et al.
1988) and schizotypy (Mohr et al. 2003a; Brugger and
Graves 1997; Taylor et al. 2002), we interpret the left-
sided veering displayed by subjects with increasing MI
scores as a consequence of a relative right-hemispheric
hyperdopaminergia. Importantly, it is the severity of ex-
clusively positive schizophrenic symptoms or positive
Fig. 1 Relationship between schizotypy scale scores (a Magical Ideation, b Physical Anhedonia) and lateral deviations in veering (difference score: positive values indicate
left-sided deviations and negative values right-sided deviations). Data are presented for the two substance groups separately (levodopa group (n = 19): small black circles,
straight regression line; placebo group (n = 21): large gray circles, dotted regression line)
a) b)
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features of schizotypy,respectively, that correlated to the
size of these asymmetries in spatial orientation. In con-
trast, PhysAn is a non-clinical analogue to negative psy-
chotic symptoms (Chapman et al. 1976, 1980), linked to
a hypodopaminergic state (Davis et al. 1991). Therefore,
PhysAn would be related to a left-hemispheric hyper-
dopaminergia and, consequently a right-sided veering
bias. This is exactly the trend we found in our placebo
group.
Since DA agonists induce (Janowsky and Risch 1979;
Sekine et al. 2001) or worsen psychotic symptoms (Abi-
Dargham et al. 1998; Angrist et al. 1985; Davidson et al.
1987), we expected that a levodopa supplementation
would increase the right-hemispheric hyperdopaminer-
gia in subjects with high MI scores and in parallel in-
crease the left-sided veering bias. However, we rather
found a reversal of the interhemispheric DA balance as
inferred by the opposite veering preferences as a func-
tion of type of schizotypy (i. e., positive vs. negative) and
pharmacological treatment. We can only speculate
about this reversal in the levodopa group.
In patient populations, behavioral and attentional
asymmetries, and by inference, neurochemical asym-
metries, were found to be attenuated or even reversed
when treated with DA antagonists (Levine et al. 1997;
Maruff et al. 1995; Tomer and Flor-Henry 1989). While
functional interhemispheric balance might have been
restored by DA decrease in patients, a similar balancing
may occur by DA agonists in healthy subjects with high
MI scores. This dissociation between schizotypy and
schizophrenia suggests the existence of neurochemical
differences between these populations, at least with re-
gard to positive symptoms.Levodopa seemed to have re-
stored interhemispheric DA symmetry, rather than ex-
aggerating asymmetry. Thus, as speculated for subjects
with a schizotypal personality disorder (Kirrane and
Siever 2000; Shihabuddin et al. 2001; Siever and Davis,
2004), protective brain mechanisms might also be active
in schizotypal subjects (see also Mohr et al., in press, for
similar conclusions drawn from findings obtained from
the same population using a completely different exper-
imental paradigm, i.e, a visuo-motor computer task).
This may explain why even large longitudinal studies on
subjects with high MI scores, as undertaken by the
Chapman group (Chapman et al. 1994; Kwapil et al.
1997), failed to convincingly predict a later psychotic
breakdown from elevated positive schizotypal features
alone (see also Verdoux and van Os 2002).
The second unexpected finding concerns the veering
behavior with respect to PhysAn scores in the levodopa
treated group. Elevated PhysAn scores were related to a
“pathological” left-sided veering bias similar to that ob-
served for elevated MI scores in the placebo group. Pre-
vious studies already claimed that along the schizophre-
nia spectrum from normality to schizophrenia,
depressive or negative schizotypal states precede schiz-
ophrenia (Meehl 1962; Tsuang et al. 2002; van Os et al.
1999). Anhedonia has not only been understood as a
negative symptom of schizophrenia or schizotypy, but
also as a core feature of depression (Loas et al.1999) and,
in pharmacological terms, was associated with a defi-
ciency of dopaminergic function (Davis et al. 1991;
Brown and Gershon 1993). Moreover, apart from an en-
hanced rate of psychosis, high schizotypal subjects also
revealed a high rate of mood disorders in a longitudinal
study (Chapman et al. 1994; Kwapil et al. 1997). Our re-
sult that the veering behavior after levodopa treatment
was identically related to PhysAn scores as it was related
to MI scores after placebo treatment raises the question
whether anhedonic subjects would benefit from lev-
odopa treatment. This proposition appears particularly
warranted in view of the fact that DA antagonists have
little effects on negative symptoms in schizophrenia
(Andreasen 1995) and DA agonists might improve a hy-
pofunctional frontal system in chronic schizophrenia
(Daniel et al. 1991; Szeszko et al. 1999).
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